Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis

D Lainer-Carr, E Brahn - Nature Clinical Practice Rheumatology, 2007 - nature.com
D Lainer-Carr, E Brahn
Nature Clinical Practice Rheumatology, 2007nature.com
Angiogenesis inhibition, long studied in the treatment of malignancies, has begun to emerge
as a potential therapeutic approach in managing inflammatory arthritis, particularly
rheumatoid arthritis. The growth of new vessels is required for the development of the
rheumatoid pannus, which then leads to extensive synovial inflammation and joint
destruction. Vascular endothelial growth factor is the best studied mediator of angiogenesis,
and several therapies have been developed that specifically target this molecule. Several …
Abstract
Angiogenesis inhibition, long studied in the treatment of malignancies, has begun to emerge as a potential therapeutic approach in managing inflammatory arthritis, particularly rheumatoid arthritis. The growth of new vessels is required for the development of the rheumatoid pannus, which then leads to extensive synovial inflammation and joint destruction. Vascular endothelial growth factor is the best studied mediator of angiogenesis, and several therapies have been developed that specifically target this molecule. Several other angiogenesis mediators, such as the angiopoietin−TIE system, hypoxia inducible factor and integrin αVβ3, as well as naturally occurring inhibitors of angiogenesis, are also being investigated as potential therapeutic targets. Additionally, there are a number of drugs, including paclitaxel, 2-methoxyestradiol and fumagillin analogs, that might have a role in inhibiting angiogenesis and, thus, in treating proliferative synovitis.
nature.com